Moderna D
MRNA
Moderna company profile
- CEO
- Stéphane Bancel
- Employees
- 4,700
- Headquarters
- 325 Binney Street, Cambridge, MA 02142, US
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO date
- 7 Dec 2018
- Stock exchange
- NASDAQ
- ISIN
- US60770K1079
Website:modernatx.com
About the company
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
Employees
Moderna had about 4,700 employees at the end of fiscal year 2025 (31 December 2025), by its annual report. That is 19.0% fewer than a year before.
Employees at each fiscal year end, as the company reports them in its annual report (10-K); revenue and net income per employee are the fiscal year's over that count.
Who owns Moderna
Institutions such as funds, banks and insurers held 82.2% of Moderna's shares on 30 June 2026, 866 of them reporting holdings to the SEC; the rest is held by individual investors and other shareholders.
Shares free to trade
Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.
Common questions about Moderna
Source: Financial Modeling Prep